Pseudomonas exotoxin A: From virulence factor to anti-cancer agent

International Journal of Medical Microbiology

Volumn 299, Issue 3, 2009, Pages 161-176

  Wolf, Philipp ^a   Elsässer Beile, Ursula ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ADP ribosylation; Anti cancer agents; Cytotoxic pathways; PE based immunotoxins; Pseudomonas exotoxin A

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ANTINEOPLASTIC AGENT; BL22; IMMUNOTOXIN; IMMUNOTOXIN A5 PSEUDOMONAS EXOTOXIN 40 FUSION PROTEIN; IMMUNOTOXIN AR209 [E23 (FRAGMENT VARIABLE ANTIBODY) PSEUDOMONAS EXOTOXIN 38 FUSION PROTEIN]; IMMUNOTOXIN B1 (DISULFIDE LINKED FRAGMENT VARIABLE ANTIBODY) PSEUDOMONAS EXOTOXIN 38 FUSION PROTEIN; IMMUNOTOXIN B3 (DISULFIDE LINKED FRAGMENT VARIABLE ANTIBODY) PSEUDOMONAS EXOCOTIN 38 FUSION PROTEIN; IMMUNOTOXIN BR96 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PSEUDOMONAS EXOTOXIN 40 FUSION PROTEIN; IMMUNOTOXIN CD19 ETA; IMMUNOTOXIN CD7 ETA; IMMUNOTOXIN ERB 38; IMMUNOTOXIN G28 5 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PSEUDOMONAS EXOTOXIN 40 FUSION PROTEIN; IMMUNOTOXIN KI4(SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY) ETA; IMMUNOTOXIN LMB2; IMMUNOTOXIN MR1 (FRAGMENT VARIABLE ANTIBODY) PSEUDOMONAS EXOTOXIN 38 FUSION PROTEIN; IMMUNOTOXIN RTF (SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY) ETA; IMMUNOTOXIN SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY (FRP5) ETA; IMMUNOTOXIN TP38; IMMUNOTOXIN TP40; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN 38 FUSION PROTEIN; LMB 1; LMB1; MONOCLONAL ANTIBODY OVB3 PSEUDOMONAS EXOTOXIN FUSION PROTEIN; NBI 3001; PSEUDOMONAS EXOTOXIN; SGN 10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY MUCIN 1 ETA FUSION PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTHRALGIA; CELL KILLING; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CYTOTOXICITY; DYSPNEA; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC MALIGNANCY; HOST CELL; HUMAN; HYPOALBUMINEMIA; IMMUNOGENICITY; INJECTION SITE INFLAMMATION; LIVER TOXICITY; LUNG CANCER; LYMPHOMA; MALAISE; MEDULLOBLASTOMA; MYALGIA; NAUSEA; NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OVARY CANCER; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; RASH; SHORT SURVEY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; URINARY TRACT INFECTION; VOMITING; XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CLINICAL TRIALS AS TOPIC; EXOTOXINS; HUMANS; IMMUNOTOXINS; VIRULENCE FACTORS;

EID: 60849116672     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2008.08.003     Document Type: Short Survey

References (131)

1. Allured V.S., Collier R.J., Carroll S.F., and McKay D.B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. USA 83 (1986) 1320-1324
2. Andersson Y., Juell S., and Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int. J. Cancer 112 (2004) 475-483
3. Azemar M., Djahansouzi S., Jäger E., Solbach C., Schmidt M., Maurer A.B., Mross K., Unger C., von Minckwitz G., Dall P., Groner B., and Wels W.S. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res. Treat. 82 (2003) 155-164
4. Ball G., Durand E., Lazdunski A., and Filloux A. A novel type II secretion system in Pseudomonas aeruginosa. Mol. Microbiol. 43 (2002) 475-485
5. Baluna R., and Vitetta E.S. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37 (1997) 117-132
6. Baluna R., Rizo J., Gordon B.E., Ghetie V., and Vitetta E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA 96 (1999) 3957-3962
7. Balzar M., Winter M.J., de Boer C.J., and Litvinov S.V. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 77 (1999) 699-712
8. Bard F., Mazelin L., Pechoux-Longin C., Malhotra V., and Jurdic P. Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum. J. Biol. Chem. 278 (2003) 46601-46606
9. Barth S., Huhn M., Wels W., Diehl V., and Engert A. Construction and in vitro evaluation of RFT5(scFv)-ETA′, a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int. J. Mol. Med. 1 (1998) 249-256
10. Beattie B.K., Prentice G.A., and Merrill A.R. Investigation into the catalytic role for the tryptophan residues within domain III of Pseudomonas aeruginosa exotoxin A. Biochemistry 35 (1996) 15134-15142
11. Beers R., Chowdhury P., Bigner D., and Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res. 6 (2000) 2835-2843
12. Bendig J.W., Kyle P.W., Giangrande P.L., Samson D.M., and Azadian B.S. Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. J. R. Soc. Med. 80 (1987) 316-317
13. Benhar I., Reiter Y., Pai L.H., and Pastan I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer 62 (1995) 351-355
14. Bitter W. Secretins of Pseudomonas aeruginosa: large holes in the outer membrane. Arch. Microbiol. 179 (2003) 307-314
15. Braun P., de Groot A., Bitter W., and Tommassen J. Secretion of elastinolytic enzymes and their propeptides by Pseudomonas aeruginosa. J. Bacteriol. 180 (1998) 3467-3469
16. Chang J.H., and Kwon H.Y. Expression of 14-3-3delta, cdc2 and cyclin B proteins related to exotoxin A-induced apoptosis in HeLa S3 cells. Int. J. Immunopharmacol. 7 (2007) 1185-1191
17. Chaudhary V.K., Jinno Y., FitzGerald D., and Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. Natl. Acad. Sci. USA 87 (1990) 308-312
18. Cornelis G.R., and Van Gijsegem F. Assembly and function of type III secretory systems. Annu. Rev. Microbiol. 54 (2000) 735-774
19. Di Paolo C., Willuda J., Kubetzko S., Lauffer I., Tschudi D., Waibel R., Pluckthun A., Stahel R.A., and Zangemeister-Wittke U. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin. Cancer Res. 9 (2003) 2837-2848
20. Domenighini M., and Rappuoli R. Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. Mol. Microbiol. 21 (1996) 667-674
21. Driscoll J.A., Brody S.L., and Kollef M.H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67 (2007) 351-368
22. Duong F., Bonnet E., Geli V., Lazdunski A., Murgier M., and Filloux A. The AprX protein of Pseudomonas aeruginosa: a new substrate for the Apr type I secretion system. Gene 262 (2001) 147-153
23. Filloux A., Michel G., and Bally M. GSP-dependent protein secretion in Gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa. FEMS Microbiol. Rev. 22 (1998) 177-198
24. Folders J., Tommassen J., van Loon L.C., and Bitter W. Identification of a chitin-binding protein secreted by Pseudomonas aeruginosa. J. Bacteriol. 182 (2000) 1257-1263
25. Folders J., Algra J., Roelofs M.S., van Loon L.C., Tommassen J., and Bitter W. Characterization of Pseudomonas aeruginosa chitinase, a gradually secreted protein. J. Bacteriol. 183 (2001) 7044-7052
26. Francisco J.A., Schreiber G.J., Comereski C.R., Mezza L.E., Warner G.L., Davidson T.J., Ledbetter J.A., and Siegall C.B. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 89 (1997) 4493-4500
27. Frankel A.E., Kreitman R.J., and Sausville E.A. Targeted toxins. Clin. Cancer Res. 6 (2000) 326-334
28. Franzetti F., Cernuschi M., Esposito R., and Moroni M. Pseudomonas infections in patients with AIDS and AIDS-related complex. J. Intern. Med. 231 (1992) 437-443
29. Friedman P.N., McAndrew S.J., Gawlak S.L., Chace D., Trail P.A., Brown J.P., and Siegall C.B. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res 53 (1993) 334-339
30. Garland L., Gitlitz B., Ebbinghaus S., Pan H., de Haan H., Puri R.K., von Hoff D., and Figlin R. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J. Immunother. 28 (2005) 376-381
31. Goldberg M.R., Heimbrook D.C., Russo P., Sarosdy M.F., Greenberg R.E., Giantonio B.J., Linehan W.M., Walther M., Fisher H.A., and Messing E. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res. 1 (1995) 57-61
32. Gomez M.I., and Prince A. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7 (2007) 244-251
33. Gordon V.M., and Leppla S.H. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect. Immun. 62 (1994) 333-340
34. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., and Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63 (1995) 82-87
35. Gray G.L., Smith D.H., Baldridge J.S., Harkins R.N., Vasil M.L., Chen E.Y., and Heyneker H.L. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 81 (1984) 2645-2649
36. Green S.K., Schroth M.N., Cho J.J., Kominos S.K., and Vitanza-Jack V.B. Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa. Appl. Microbiol. 28 (1974) 987-991
37. Hafkemeyer P., Brinkmann U., Gottesman M.M., and Pastan I. Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum. Gene Ther. 10 (1999) 923-934
38. Hassan R., Lerner M.R., Benbrook D., Lightfoot S.A., Brackett D.J., Wang Q.C., and Pastan I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin. Cancer Res. 8 (2002) 3520-3526
39. Hassan R., Bullock S., Premkumar A., Kreitman R.J., Kindler H., Willingham M.C., and Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13 (2007) 5144-5149
40. Hazes B., and Read R.J. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36 (1997) 11051-11054
41. Hessler J.L., and Kreitman R.J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36 (1997) 14577-14582
42. Hjortland G.O., Garman-Vik S.S., Juell S., Olsen O.E., Hirschberg H., Fodstad O., and Engebraaten O. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J. Neurosurg. 100 (2004) 320-327
43. Hwang J., Fitzgerald D.J., Adhya S., and Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48 (1987) 129-136
44. Iglewski B.H., and Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc. Natl. Acad. Sci. USA 72 (1975) 2284-2288
45. Iglewski B.H., Liu P.V., and Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect. Immun. 15 (1977) 138-144
46. Jackson M.E., Simpson J.C., Girod A., Pepperkok R., Roberts L.M., and Lord J.M. The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. J. Cell Sci. 112 Pt 4 (1999) 467-475
47. Jain R.K. Delivery of molecular medicine to solid tumors. Science 271 (1996) 1079-1080
48. Jenkins C.E., Swiatoniowski A., Issekutz A.C., and Lin T.J. Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism. J. Biol. Chem. 279 (2004) 37201-37207
49. Jorgensen R., Merrill A.R., Yates S.P., Marquez V.E., Schwan A.L., Boesen T., and Andersen G.R. Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature 436 (2005) 979-984
50. Joshi B.H., Leland P., Silber J., Kreitman R.J., Pastan I., Berger M., and Puri R.K. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br. J. Cancer 86 (2002) 285-291
51. Kawakami K., Leland P., and Puri R.K. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 60 (2000) 2981-2987
52. Kawakami K., Kawakami M., Joshi B.H., and Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61 (2001) 6194-6200
53. Kawakami K., Kawakami M., Husain S.R., and Puri R.K. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 62 (2002) 3575-3580
54. Kielhofner M., Atmar R.L., Hamill R.J., and Musher D.M. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect. Dis. 14 (1992) 403-411
55. Klimka A., Barth S., Matthey B., Roovers R.C., Lemke H., Hansen H., Arends J.W., Diehl V., Hoogenboom H.R., and Engert A. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line. Br. J. Cancer 80 (1999) 1214-1222
56. Komatsu N., Oda T., and Muramatsu T. Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin. J. Biochem. (Tokyo) 124 (1998) 1038-1044
57. Koopmann J.O., Albring J., Huter E., Bulbuc N., Spee P., Neefjes J., Hämmerling G.J., and Momburg F. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 13 (2000) 117-127
58. Kounnas M.Z., Morris R.E., Thompson M.R., FitzGerald D.J., Strickland D.K., and Saelinger C.B. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem. 267 (1992) 12420-12423
59. Kreitman R.J., and Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 307 Pt 1 (1995) 29-37
60. Kreitman R.J., Chaudhary V.K., Kozak R.W., FitzGerald D.J., Waldman T.A., and Pastan I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 80 (1992) 2344-2352
61. Kreitman R.J., Bailon P., Chaudhary V.K., FitzGerald D.J., and Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 83 (1994) 426-434
62. Kreitman R.J., Margulies I., Stetler-Stevenson M., Wang Q.C., FitzGerald D.J., and Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res. 6 (2000) 1476-1487
63. Kreitman R.J., Wilson W.H., White J.D., Stetler-Stevenson M., Jaffe E.S., Giardina S., Waldmann T.A., and Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18 (2000) 1622-1636
64. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., and Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 (2001) 241-247
65. Kreitman R.J., Squires D.R., Stetler-Stevenson M., Noel P., FitzGerald D.J., Wilson W.H., and Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23 (2005) 6719-6729
66. Kunwar S., Pai L.H., and Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J. Neurosurg. 79 (1993) 569-576
67. Leland P., Taguchi J., Husain S.R., Kreitman R.J., Pastan I., and Puri R.K. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol. Med. 6 (2000) 165-178
68. Letoffe S., Redeker V., and Wandersman C. Isolation and characterization of an extracellular haem-binding protein from Pseudomonas aeruginosa that shares function and sequence similarities with the Serratia marcescens HasA haemophore. Mol. Microbiol. 28 (1998) 1223-1234
69. Li M., Dyda F., Benhar I., Pastan I., and Davies D.R. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog, implications for the activation process and for ADP ribosylation. Proc. Natl. Acad. Sci. USA 93 (1996) 6902-6906
70. Liu P.V. Extracellular toxins of Pseudomonas aeruginosa. J. Infect. Dis. 130 Suppl. (1974) S94-S99
71. Lombardi D., Soldati T., Riederer M.A., Goda Y., Zerial M., and Pfeffer S.R. Rab9 functions in transport between late endosomes and the trans Golgi network. EMBO J. 12 (1993) 677-682
72. Martinez A., Ostrovsky P., and Nunn D.N. Identification of an additional member of the secretin superfamily of proteins in Pseudomonas aeruginosa that is able to function in type II protein secretion. Mol. Microbiol. 28 (1998) 1235-1246
73. Maschmeyer G., and Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 19 (2000) 915-925
74. McKee M.L., and FitzGerald D.J. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 38 (1999) 16507-16513
75. Michl P., and Gress T.M. Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr. Cancer Drug Targets 4 (2004) 689-702
76. Miesenbock G., and Rothman J.E. The capacity to retrieve escaped ER proteins extends to the trans-most cisterna of the Golgi stack. J. Cell Biol. 129 (1995) 309-319
77. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 327 Pt 3 (1997) 625-635
78. Ogata M., Chaudhary V.K., Pastan I., and FitzGerald D.J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem. 265 (1990) 20678-20685
79. Ogata M., Fryling C.M., Pastan I., and FitzGerald D.J. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem. 267 (1992) 25396-25401
80. Okino N., Ichinose S., Omori A., Imayama S., Nakamura T., and Ito M. Molecular cloning, sequencing, and expression of the gene encoding alkaline ceramidase from Pseudomonas aeruginosa. Cloning of a ceramidase homologue from Mycobacterium tuberculosis. J. Biol. Chem. 274 (1999) 36616-36622
81. Onda M., Olafsen T., Tsutsumi Y., Bruland O.S., and Pastan I. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J. Immunother. 24 (2001) 144-150
82. Onda M., Wang Q.C., Guo H.F., Cheung N.K., and Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 64 (2004) 1419-1424
83. Onda M., Nagata S., FitzGerald D.J., Beers R., Fisher R.J., Vincent J.J., Lee B., Nakamura M., Hwang J., Kreitman R.J., Hassan R., and Pastan I. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol. 177 (2006) 8822-8834
84. Ortiz P.A., and Kinzy T.G. Dominant-negative mutant phenotypes and the regulation of translation elongation factor 2 levels in yeast. Nucleic Acids Res. 33 (2005) 5740-5748
85. Ostroff R.M., Vasil A.I., and Vasil M.L. Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa. J. Bacteriol. 172 (1990) 5915-5923
86. Pai L.H., Gallo M.G., FitzGerald D.J., and Pastan I. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). Cancer Res. 51 (1991) 2808-2812
87. Pai L.H., Wittes R., Setser A., Willingham M.C., and Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 2 (1996) 350-353
88. Pai-Scherf L.H., Villa J., Pearson D., Watson T., Liu E., Willingham M.C., and Pastan I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res. 5 (1999) 2311-2315
89. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim. Biophys. Acta 1333 (1997) C1-C6
90. Peipp M., Kupers H., Saul D., Schlierf B., Greil J., Zunino S.J., Gramatzki M., and Fey G.H. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 62 (2002) 2848-2855
91. Pelham H.R., Roberts L.M., and Lord J.M. Toxin entry: how reversible is the secretory pathway?. Trends Cell Biol. 2 (1992) 183-185
92. Posey J.A., Khazaeli M.B., Bookman M.A., Nowrouzi A., Grizzle W.E., Thornton J., Carey D.E., Lorenz J.M., Sing A.P., Siegall C.B., LoBuglio A.F., and Saleh M.N. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res. 8 (2002) 3092-3099
93. Proud C.G. Peptide-chain elongation in eukaryotes. Mol. Biol. Rep. 19 (1994) 161-170
94. Rand R.W., Kreitman R.J., Patronas N., Varricchio F., Pastan I., and Puri R.K. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6 (2000) 2157-2165
95. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. 81 (2001) 93-124
96. Reiter Y., and Pastan I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin. Cancer Res. 2 (1996) 245-252
97. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 352 (2005) 1992-2001
98. Sampson J.H., Akabani G., Archer G.E., Bigner D.D., Berger M.S., Friedman A.H., Friedman H.S., Herndon II J.E., Kunwar S., Marcus S., McLendon R.E., Paolino A., Penne K., Provenzale J., Quinn J., Reardon D.A., Rich J., Stenzel T., Tourt-Uhlig S., Wikstrand C., Wong T., Williams R., Yuan F., Zalutsky M.R., and Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65 (2003) 27-35
99. Sarosdy M.F., Hutzler D.H., Yee D., and von Hoff D.D. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. J. Urol. 150 (1993) 1950-1955
100. Schmidt M., McWatters A., White R.A., Groner B., Wels W., Fan Z., and Bast Jr. R.C. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol. Oncol. 80 (2001) 145-155
101. Schümann J., Angermüller S., Bang R., Lohoff M., and Tiegs G. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J. Immunol. 161 (1998) 5745-5754
102. Schwemmlein M., Stieglmaier J., Kellner C., Peipp M., Saul D., Oduncu F., Emmerich B., Stockmeyer B., Lang P., Beck J.D., and Fey G.H. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia 21 (2007) 1405-1412
103. Shinohara H., Fan D., Ozawa S., Yano S., Van Arsdell M., Viner J.L., Beers R., Pastan I., and Fidler I.J. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int. J. Oncol. 17 (2000) 643-651
104. Siegall C.B., Chaudhary V.K., FitzGerald D.J., and Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem. 264 (1989) 14256-14261
105. Siegall C.B., Liggitt D., Chace D., Tepper M.A., and Fell H.P. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc. Natl. Acad. Sci. USA 91 (1994) 9514-9518
106. Siegall C.B., Liggitt D., Chace D., Mixan B., Sugai J., Davidson T., and Steinitz M. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin. Cancer Res. 3 (1997) 339-345
107. Siegall C.B., Haggerty H.G., Warner G.L., Chace D., Mixan B., Linsley P.S., and Davidson T. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. J. Immunol. 159 (1997) 5168-5173
108. Singh R., Samant U., Hyland S., Chaudhari P.R., Wels W.S., and Bandyopadhyay D. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol. Cancer Ther. 6 (2007) 562-569
109. Skrepnik N., Araya J.C., Qian Z., Xu H., Hamide J., Mera R., and Hunt J.D. Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin. Cancer Res. 2 (1996) 1851-1857
110. Skrepnik N., Zieske A.W., Bravo J.C., Gillespie A.T., and Hunt J.D. Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. J. Urol. 161 (1999) 984-989
111. Smith D.C., Spooner R.A., Watson P.D., Murray J.L., Hodge T.W., Amessou M., Johannes L., Lord J.M., and Roberts L.M. Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 7 (2006) 379-393
112. Steinstraesser L., Oezdogan Y., Wang S.C., and Steinau H.U. Host defense peptides in burns. Burns 30 (2004) 619-627
113. Strome S.E., Kawakami K., Alejandro D., Voss S., Kasperbauer J.L., Salomao D., Chen L., Maki R.A., and Puri R.K. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin. Cancer Res. 8 (2002) 281-286
114. Theuer C.P., Buchner J., FitzGerald D., and Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc. Natl. Acad. Sci. USA 90 (1993) 7774-7778
115. Tsutsumi Y., Onda M., Nagata S., Lee B., Kreitman R.J., and Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97 (2000) 8548-8553
116. Vasil M.L. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. J. Pediatr. 108 (1986) 800-805
117. Vitetta E.S. Immunotoxins and vascular leak syndrome. Cancer J. 6 Suppl. 3 (2000) S218-S224
118. von Minckwitz G., Harder S., Hovelmann S., Jäger E., Al-Batran S.E., Loibl S., Atmaca A., Cimpoiasu C., Neumann A., Abera A., Knuth A., Kaufmann M., Jäger D., Maurer A.B., and Wels W.S. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 7 (2005) R617-R626
119. Wang L., Liu B., Schmidt M., Lu Y., Wels W., and Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 47 (2001) 21-28
120. Weber F., Asher A., Bucholz R., Berger M., Prados M., Chang S., Bruce J., Hall W., Rainov N.G., Westphal M., Warnick R.E., Rand R.W., Floeth F., Rommel F., Pan H., Hingorani V.N., and Puri R.K. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol. 64 (2003) 125-137
121. Wedekind J.E., Trame C.B., Dorywalska M., Koehl P., Raschke T.M., McKee M., FitzGerald D., Collier R.J., and McKay D.B. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J. Mol. Biol. 314 (2001) 823-837
122. Wels W., Harwerth I.M., Mueller M., Groner B., and Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52 (1992) 6310-6317
123. White J., Johannes L., Mallard F., Girod A., Grill S., Reinsch S., Keller P., Tzschaschel B., Echard A., Goud B., and Stelzer E.H. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. J. Cell Biol. 147 (1999) 743-760
124. Wilderman P.J., Vasil A.I., Johnson Z., Wilson M.J., Cunliffe H.E., Lamont I.L., and Vasil M.L. Characterization of an endoprotease (PrpL) encoded by a PvdS-regulated gene in Pseudomonas aeruginosa. Infect. Immun. 69 (2001) 5385-5394
125. Willingham M.C., FitzGerald D.J., and Pastan I. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc. Natl. Acad. Sci. USA 84 (1987) 2474-2478
126. Wilson D.W., Lewis M.J., and Pelham H.R. pH-dependent binding of KDEL to its receptor in vitro. J. Biol. Chem. 268 (1993) 7465-7468
127. Wolf P., Gierschner D., Bühler P., Wetterauer U., and Elsässer-Beile U. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol. Immunother. 55 (2006) 1367-1373
128. Wolf P., Alt K., Bühler P., Katzenwadel A., Wetterauer U., Tacke M., and Elsässer-Beile U. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate 68 (2008) 129-138
129. Wong B.Y., Gregory S.A., and Dang N.H. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest. 25 (2007) 495-501
130. Yates S.P., and Merrill A.R. Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A. Biochem. J. 379 (2004) 563-572
131. Yates S.P., Jorgensen R., Andersen G.R., and Merrill A.R. Stealth and mimicry by deadly bacterial toxins. Trends Biochem. Sci. 31 (2006) 123-133